Evidence map›Paper›PMID 28848822›Full record

ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2014

Longitudinal Computed Tomography and Magnetic Resonance Imaging of COPD: Thoracic Imaging Network of Canada (TINCan) Study Objectives.

Miranda Kirby, Damien Pike, David G McCormack, Stephen Lam, Harvey O Coxson, Grace Parraga

Open access · bronzeAbstract read
In one paragraph

Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Undersampled Diffusion-WeightedDiagnostics (Basel, Switzerland) · 2023
    Article
  5. BMJ open respiratory research · 2022
    Article
  6. Article
  7. Developing and Implementing Biomarkers and Novel Imaging in COPD.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Miranda KirbyDepartment of Radiology, University of British Columbia, Vancouver, Canada.
Damien PikeImaging Research Laboratories, Robarts Research Institute, University of Western Ontario, London, Canada.
David G McCormackUniversity of British Columbia, James Hogg Research Center and The Institute of Heart and Lung Health, St. Paul's Hospital, Vancouver, Canada.
Stephen LamDepartment of Integrative Oncology, British Columbia Cancer Agency Research Centre, Vancouver, Canada.
Harvey O CoxsonDepartment of Radiology, University of British Columbia, Vancouver, Canada.
Grace ParragaImaging Research Laboratories, Robarts Research Institute, University of Western Ontario, London, Canada.
St. Paul's Hospital · CAWestern University · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the human and societal burden and cost of COPD is staggering, there are few clinical tools that provide earlier diagnoses or a means to regionally monitor disease in a way that might lead to improved therapies and outcomes. In acknowledgement of the current gaps in COPD therapy, the objective of the Thoracic Imaging Network of Canada (TINCan) is to improve COPD patient phenotyping through imaging, to provide methods and imaging-based intermediate endpoints for the development of new treatments, and to evaluate disease progression and patient-based outcomes in COPD patients and those at risk of COPD. Here we summarize and outline the TINCan study protocol and describe our objectives. TINCan is a prospective study that aims to identify and quantify novel COPD phenotypes from thoracic computed tomography (CT) and thoracic hyperpolarized noble gas magnetic resonance imaging (MRI) in 200 ex-smokers, 50 years of age or greater, including asymptomatic ex-smokers with normal pulmonary function and Global initiative for chronic Obstructive Lung Disease (GOLD) Unclassified (U) , and GOLD stages I-IV patients. Baseline and 2-year follow-up measurements will be acquired using spirometry, plethysmography, diffusing capacity of the lung for carbon monoxide (DL

Indexed as

airways diseaseCTemphysemaimaging phenotypesMRI

Identifiers

PMID28848822
PMCPMC5556865
OpenAlexW2324542191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.